University of Groningen Developments in the treatment of advanced melanoma Sloot, Sarah

University of Groningen

Developments in the treatment of advanced melanoma

Sloot, Sarah

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Sloot, S. (2017). Developments in the treatment of advanced melanoma. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Colofon

Cover design

Catrin Welz-Stein

www.facebook.com/CWelzStein

Layout

FYN Werk, Fleur Bominaar www.fynwerk.nl

Printed by

Gildeprint, Enschede www.gildeprint.nl

Financial support

The author gratefully acknowledges financial support from the Groningen Melanoma Sarcoma Foundation to conduct research at Moffitt Cancer Center and from Pfizer Inc. for the printing of this dissertation.

ISBN: 978-94-6233-755-8 © Sarah Sloot, The Netherlands All rights reserved. No part of this book may be reproduced, stored in a retreival system or transmitted in any form without prior permission of the author.

Developments in the treatment

of advanced melanoma

PhD thesis

to obtain the degree of PhD at

the University of Groningen

under the authority of the

Rector Magnificus Prof. E. Sterken

and in accordance with

the decision by the College of Deans.

This dissertation will be defended in public on

Wednesday 22 November 2017 at 12.45 hours

by

Sarah Sloot

born on 14 April 1988

in Walenstadt, Zwitserland

Supervisor

Prof. H.J. Hoekstra

Co-supervisors

Prof. J.S. Zager

Prof. G.T. Gibney

Paranymphs

1.

2.

Part I

Locoregional treatment developments

in advanced melanoma

3.

treatment and the development of intralymphatic metastasis? A review of the literature 53

Sarah Sloot, MD; Maarten J. Speijers, MD; Esther Bastiaannet, PhD; Harald J. Hoekstra, MD, PhD.

Cancer Treat Rev 2016, 45:120-8

4.

percutaneous hepatic perfusion 73

Omar M. Rashid, MD JD; Sarah Sloot, MD; Jonathan S. Zager, MD.

Expert Opin Drug Metab Toxicol 2014, 10(10):1355-1364

Part II

BRAF treatment in advanced melanoma

5.

Sarah Sloot, MD; Omar M. Rashid, MD JD; Amod A. Sarnaik, MD; Jonathan S. Zager, MD.

Cancer Control 2016, 23(1):12-20

6.

a potential neoadjuvant strategy 115

Sarah Sloot, MD; Jonathan S. Zager, MD; Ragini R. Kudchadkar, MD; Jane L. Messina, MD; Jacob J. Benedict; Ricardo J. Gonzalez, MD; Ronald DeConti, MD; Leslie M. Turner, MD; Timothy McCardle; Keiran S.M. Smalley, PhD; Jeffrey S. Weber, MD PhD;

Vernon K. Sondak, MD; Geoffrey T. Gibney, MD.

Melanoma Res 2016, 26:83-87

7.

treatment: friend or foe? 127

Sarah Sloot, MD; Inna V. Fedorenko; Keiran S.M. Smalley, PhD; Geoffrey T. Gibney, MD.

Expert Opin Pharmacother 2014 15(5):589-592

Part III

Developments in melanoma brain metastasis

8.

survival of patients with melanoma brain metastases in

the era of targeted BRAF and immune checkpoint therapies 139

Sarah Sloot, MD; Yian A. Chen, PhD; Xiuhua Zhao, PhD;

Jamie L. Weber, MD; Jacob J. Benedict, MD; James J. Mulé, PhD; Keiran S. Smalley, PhD; Jeffrey S. Weber, MD, PhD;

Jonathan S. Zager, MD; Peter A. Forsyth, MD; Vernon K. Sondak, MD; Geoffrey T. Gibney, MD.

Cancer (accepted) June, 2017

9.

10.

11.

Contents